We are live on ! Find out more
TCRT icon

Alaunos Therapeutics

124 hedge funds and large institutions have $90.5M invested in Alaunos Therapeutics in 2022 Q2 according to their latest regulatory filings, with 21 funds opening new positions, 21 increasing their positions, 42 reducing their positions, and 42 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,963% more call options, than puts

Call options by funds: $10.1M | Put options by funds: $491K

38% more capital invested

Capital invested by funds: $65.9M → $90.5M (+$24.7M)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

0.08% less ownership

Funds ownership: 0.31%0.23% (-0.08%)

16% less funds holding

Funds holding: 148124 (-24)

50% less first-time investments, than exits

New positions opened: 21 | Existing positions closed: 42

50% less repeat investments, than reductions

Existing positions increased: 21 | Existing positions reduced: 42

Holders
124
Holders Change
-24
Holders Change %
-16.22%
% of All Funds
2.09%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.02%
New
21
Increased
21
Reduced
42
Closed
42
Calls
$10.1M
Puts
$491K
Net Calls
+$9.64M
Net Calls Change
+$4.38M

TCRT Hedge Fund Activity: Q2 2022 in Review

124 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Alaunos Therapeutics (TCRT) for Q2 2022, worth a combined $90.5M — up 38% from $65.9M a quarter earlier.

Sellers outnumbered buyers: 42 funds closed out of TCRT and 21 opened new positions — a net loss of 21 holders — while 42 trimmed existing stakes and 21 added.

The largest buyer was Laurion Capital Management, opening a new position worth an estimated $2.73M. The largest seller was BlackRock, cutting an estimated $7.31M.

  • 124 institutional investors held Alaunos Therapeutics (TCRT) as of Q2 2022, down from 148 in Q1 2022.
  • Funds reported $90.5M of Alaunos Therapeutics stock for Q2 2022, up 38% quarter-over-quarter.
  • 21 funds opened new Alaunos Therapeutics positions in Q2 2022 and 42 closed out, a net change of -21 holders.
  • The largest Alaunos Therapeutics buyer in Q2 2022 was Laurion Capital Management, an estimated $2.73M added.
  • The largest Alaunos Therapeutics seller in Q2 2022 was BlackRock, an estimated $7.31M sold.

Based on aggregated 13F filings for Q2 2022.